Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2026-01-21 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
董事会议事规则（草案）（H股发行并上市后适用）
Governance Information Classification · 95% confidence The document is titled '董事会议事规则' which translates to 'Rules of Procedure for the Board of Directors'. It details the internal rules, decision-making processes, meeting procedures, voting protocols, and responsibilities of the board of directors of Shenzhen Salubris Pharmaceuticals Co., Ltd. It references company law, stock exchange listing rules, and company articles of association. The content is focused on governance structure and board operations rather than financial results, audit opinions, or shareholder meeting materials. There is no indication that this is an announcement or a report of financial results or voting outcomes. The document is a governance document outlining the board's internal rules and procedures, fitting the definition of Governance Information (CGR). The document length (8184 characters) and detailed procedural content support this classification with high confidence.
2026-01-21 Chinese
关联（连）交易决策制度（草案）（H股发行并上市后适用）
Governance Information Classification · 95% confidence The document is titled '关联（连）交易决策制度' which translates to 'Related Party Transaction Decision System'. It is a detailed policy document outlining the principles, definitions, decision procedures, disclosure requirements, and governance related to related party transactions for Shenzhen Salubris Pharmaceuticals Co., Ltd. It references compliance with Chinese company law, securities law, Shenzhen Stock Exchange listing rules, and Hong Kong Stock Exchange listing rules. The document is a governance and compliance manual rather than a financial report, announcement, or regulatory filing. It does not contain financial statements, earnings data, voting results, or transaction announcements. It is a governance-related internal rules document detailing how the company manages related party transactions, including board and shareholder approval processes, disclosure, and compliance with listing rules. Therefore, the most appropriate classification is Governance Information (CGR). The document length (11,889 characters) supports it being a full policy document rather than a brief announcement or notice.
2026-01-21 Chinese
独立董事工作制度（草案）（H股发行并上市后适用）
Governance Information Classification · 95% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System'. It details the governance structure, qualifications, duties, rights, and obligations of independent directors in the company, referencing relevant laws and stock exchange rules, including the Hong Kong Stock Exchange Listing Rules. The content is a governance framework document rather than a financial report, earnings release, or announcement. It is a detailed internal governance policy document related to board structure and director responsibilities. This fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length (7616 characters) and detailed content support this classification with high confidence.
2026-01-21 Chinese
境外发行证券与上市相关保密和档案管理工作制度
Governance Information Classification · 95% confidence The document is a detailed internal policy titled '境外发行证券和上市相关保密和档案管理工作制度' (Confidentiality and Archive Management System for Overseas Securities Issuance and Listing) issued by the company's board. It outlines procedures and legal compliance related to confidentiality and document management during overseas securities issuance and listing processes. There are no financial statements, earnings data, voting results, or announcements of report publications. The document is a governance-related internal regulation concerning company practices and compliance. Therefore, it fits best under Governance Information (CGR). The document length is 3486 characters, which is relatively short but contains substantive policy content rather than a mere announcement or certification, so it is not RPA or RNS.
2026-01-21 Chinese
对外担保管理办法（草案）（H股发行并上市后适用）
Governance Information Classification · 95% confidence The document is titled '对外担保管理办法' which translates to 'External Guarantee Management Measures'. It is a detailed internal policy document outlining the procedures, approvals, and regulations related to the company's external guarantees, including references to relevant laws and stock exchange rules. It is not a financial report, earnings release, or announcement of voting results. It is a governance-related document detailing internal rules and procedures for managing external guarantees. The document length is 2583 characters, which is relatively short but contains substantive policy content rather than a mere announcement. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules and governance practices.
2026-01-21 Chinese
内幕信息知情人登记制度（草案）（H股发行并上市后适用）
Governance Information Classification · 95% confidence The document is titled '内幕信息知情人登记制度' which translates to 'Insider Information Insider Registration System'. It is a detailed internal policy document outlining the management, registration, and confidentiality obligations related to insider information for Shenzhen Salubris Pharmaceuticals Co., Ltd. It references various laws and regulations related to securities and insider information management, including the Securities Law, Company Law, and listing rules. The document is a regulatory compliance and governance policy rather than a financial report, earnings release, or announcement. It does not contain financial statements, earnings data, or voting results. It is not a report publication announcement or a certification. The content fits best under Governance Information (CGR) as it details internal rules and governance practices related to insider information management and compliance.
2026-01-21 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.